Core Points - A class action lawsuit has been filed against Integer Holdings Corporation on behalf of investors who acquired its securities between July 25, 2024, and October 22, 2025 [1][2] - The lawsuit alleges that Integer made misleading statements and omitted critical information regarding its business operations, including overstating its market position and failing to disclose a decline in sales of electrophysiology devices [3] - Following a reduction in sales guidance announced on October 23, 2025, Integer's stock price dropped by $35.22 per share, representing a decline of over 32% in one day [3] Company Overview - Integer Holdings Corporation is a global medical device company headquartered in Plano, Texas [2] - The company is involved in the development and manufacturing of medical devices, with a focus on electrophysiology products [3] Legal Context - Investors who purchased Integer securities during the specified class period have until February 9, 2026, to seek appointment as lead plaintiff representatives [2] - The law firm Berger Montague PC, known for handling complex civil litigation and class actions, is representing the plaintiffs in this case [4]

Group 1 - A hedge fund with over a 3% stake in Integer has sent a letter to the company's board outlining its requests [1]

Core Viewpoint - Integer Holdings Corporation is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its competitive position and sales performance in the electrophysiology manufacturing market [3]. Group 1: Allegations - The complaint alleges that Integer overstated its competitive position within the growing electrophysiology manufacturing market [3]. - Despite claims of strong visibility into customer demand, the company was experiencing a sustained deterioration in sales related to two of its electrophysiology devices [3]. - Integer mischaracterized its electrophysiology devices as a long-term growth driver for its cardio & vascular segment [3]. - As a result, the defendants' positive statements about the company's business, operations, and prospects were materially false and misleading [3]. Group 2: Class Action Details - The class period for the lawsuit is from July 25, 2024, to October 22, 2025 [3]. - Shareholders who purchased shares during this period are encouraged to register for the class action, with a deadline to seek lead plaintiff status set for February 9, 2026 [4]. - There is no cost or obligation for shareholders to participate in the case [4].

PHILADELPHIA, Dec. 17, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) ("Integer" or the "Company") on behalf of investors who purchased or otherwise acquired Integer securities during the period of July 25, 2024 through October 22, 2025 (the "Class Period"), inclusive. Investor Deadline: Investors who purchased Integer securities during the Class Period may, no later than February 9 ...

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, significantly below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly misleading investors regarding its business performance and sales forecasts, leading to significant stock price declines [1][5]. Group 1: Company Performance - On October 23, 2025, Integer reduced its full-year 2025 sales guidance to a range of $1.840 billion to $1.854 billion, which was below prior expectations [3]. - The company anticipated net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, indicating a slowdown in growth [3]. - Management revealed that sales of three new products, including two electrophysiology devices, were expected to decline in 2026 due to slower market adoption [3]. Group 2: Stock Impact - Following the announcement of reduced sales guidance, Integer's stock price fell by $35.22 per share, or 32.3%, closing at $73.89 per share on October 23, 2025 [4]. Group 3: Allegations in the Lawsuit - The lawsuit alleges that Integer made materially false and misleading statements about its competitive position in the electrophysiology (EP) manufacturing market [5]. - It is claimed that the company overstated its visibility into customer demand and mischaracterized its EP devices as long-term growth drivers for its Cardio & Vascular segment [5]. - The lawsuit contends that the positive statements made by the company lacked a reasonable basis and were materially misleading [5].

NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Integer Holdings Corporation (“Integer” or the “Company”) (NYSE: ITGR) between July 25, 2024 through October 22, 2025, inclusive. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of Integer Holdings Corporation (NYSE: ITGR)?Did you purchase your shares between Jul ...

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly misleading investors regarding its business performance and sales forecasts during the specified Class Period [1][5]. Group 1: Company Performance - On October 23, 2025, Integer reduced its full-year 2025 sales guidance to a range of $1.840 billion to $1.854 billion, which was below prior expectations [3]. - The company anticipated net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, indicating a slowdown in growth [3]. - Management revealed that sales of three new products, including two electrophysiology devices, were expected to decline in 2026 due to slower market adoption [3]. Group 2: Stock Impact - Following the announcement of reduced sales guidance, Integer's stock price fell by $35.22 per share, or 32.3%, closing at $73.89 per share on October 23, 2025 [4]. Group 3: Allegations in the Lawsuit - The lawsuit alleges that Integer made materially false and misleading statements about its competitive position in the electrophysiology (EP) manufacturing market [5]. - It is claimed that the company overstated its visibility into customer demand and mischaracterized its EP devices as long-term growth drivers for its Cardio & Vascular segment [5]. - The lawsuit contends that the positive statements made by the company regarding its business and prospects were materially misleading and lacked a reasonable basis [5].

LOS ANGELES, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Integer Holdings Corporation (“Integer” or “the Company”) (NYSE: ITGR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s securities between July 25, 2024 and October 22, 2025, inclusive (the “Clas ...

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Integer Holdings Corporation designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company has been accused of overstating demand for its electrophysiology devices while publicly assuring strong sales growth [4]. Group 3: Financial Performance - Integer's stock price dropped by $35.22 per share, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025, following the announcement of lowered sales guidance [6]. - The revised sales guidance for 2025 was lowered to a range of $1.840 billion to $1.854 billion, down from $1.850 billion to $1.876 billion, which was below analysts' estimates [6]. - The company projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, citing slower adoption of two of its electrophysiology devices [6][5].